New Oral Weight Loss Drugs: Where Are We and What's Next?
Jun 5, 2024 · The company also announced that the US Food and Drug Administration has approved an expansion of the trial's protocol to investigate the contribution of circadian effects in weight loss treatment ...
FDA Approves Liraglutide ( Saxenda ) for Weight Loss - Medscape
Dec 23, 2014 · The FDA approved liraglutide for weight loss under a risk evaluation and mitigation strategy consisting of a communication plan to inform healthcare providers about the serious risks of the drug ...
FDA Approves 'Game Changer' Semaglutide for Weight Loss
Jun 4, 2021 · The mean 15% weight loss at 68 weeks is nearly twice what is seen with other FDA-approved anti-obesity medications, he noted, and moreover, 70% of patients taking semaglutide lost at least 10% of ...
The Truth About Compounded GLP-1s That Doctors Need to …
Mar 26, 2024 · Unfortunately, the high demand for these new weight loss medications has resulted in a frustrating, long-lasting shortage. The manufacturers of the two FDA-approved drugs, Novo Nordisk and Eli ...
FDA Approves Semaglutide for Cardiovascular Risk Reduction
Mar 8, 2024 · The US Food and Drug Administration (FDA) has approved the anti-obesity drug semaglutide 2.4 mg injection (Wegovy) ... The makers of the weight loss medication, Novo Nordisk, has also filed for a ...
FDA Approves Another Balloon Device for Weight Loss - Medscape
Aug 7, 2015 · Following on the heels of its approval of the ReShape device, the FDA has now approved a second intragastric balloon for weight loss in people with a BMI of 30 to 40.
FDA Approves Tirzepatide for Treating Obesity - Medscape
Nov 8, 2023 · Eli Lilly & Company will market tirzepatide injections for weight management under the trade name Zepbound. It was approved in May 2022 for treating type 2 diabetes.The new indication is for ...
Quick Takes: The 5 FDA-Approved Obesity Drugs - Medscape
Mar 2, 2017 · Quick Takes: What You Need to Know About The 5 FDA-Approved Obesity Drugs. ... 5%-15% weight loss, which usually leads to significant improvements in many comorbid conditions, including ...
FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and …
Jan 3, 2023 · FDA approves semaglutide 2.4mg (Wegovy), a once-weekly subcutaneous injection, for treating obesity in adolescents aged 12 years and older. ... The US Food and Drug Administration has approved ...
Swallowable Intragastric Balloon Shows Significant Weight Loss
Jan 12, 2022 · However, a separate meta-analysis showed the pooled percentage of total body weight loss with the FDA-approved Orbera balloon to be about the same as the current Allurion analysis, at 12.3% at 3 ...